| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.9M | — | +8.0% |
| SG&A Expense | $2.9M | — | +2.3% |
| Operating Income | -$6.8M | — | -5.5% |
| Net Income | -$6.7M | — | -4.5% |
| EPS (Basic) | -$6.41 | — | -46.0% |
| EPS (Diluted) | -$6.41 | — | -46.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $14.5M | -32.8% | +579.1% |
| Current Assets | $16.0M | -30.7% | +343.1% |
| Total Assets | $19.9M | -26.8% | +138.6% |
| Current Liabilities | $4.8M | -21.3% | -11.7% |
| Total Liabilities | $8.3M | -15.5% | -15.5% |
| Stockholders' Equity | $11.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.0M | — | -21.1% |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $871K | — | — |
| +888.3% |